News
THRX
6.10
0.00%
0.00
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapie...
PR Newswire · 09/06 12:30
Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Theseus Pharmaceuticals press release (<span...
Seekingalpha · 08/11 13:29
BRIEF-Theseus Pharmaceuticals reports Q2 results
BRIEF-Theseus Pharmaceuticals reports Q2 results
Reuters · 08/11 11:07
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapie...
PR Newswire · 08/03 12:30
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
Benzinga · 07/01 16:48
Theseus Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated coverage of Theseus Pharmaceuticals (THRX) with a Buy ...
Seekingalpha · 06/30 19:01
HC Wainwright Initiates Coverage on Theseus Pharmaceuticals With Buy Rating, $22 Price Target
MT Newswires · 06/30 09:31
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/16 10:22
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 36 companies achieved new lows for the year.
Benzinga · 05/31 16:06
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapie...
PR Newswire · 05/19 12:30
BRIEF-Theseus Pharmaceuticals Inc - On May 17, Board Expanded Size Of Board From Five To Six Directors
reuters.com · 05/18 22:00
BRIEF-Theseus Pharmaceuticals Appoints Don Hayden To Board Of Directors
reuters.com · 05/18 12:30
Theseus Pharmaceuticals declares $0.46 dividend
Theseus Pharmaceuticals (NASDAQ:THRX) declares $0.46/share quarterly dividend, in line with previous. Forward yield 23.74% Payable June 24; for shareholders of record June 8; ex-div May 7. See THRX Dividend Scorecard,
Seekingalpha · 05/13 14:20
Theseus Pharmaceuticals GAAP EPS of -$0.27
Theseus Pharmaceuticals press release (NASDAQ:THRX): GAAP EPS of -$0.27. As of March 31, 2022, Theseus had cash, cash equivalents and short-term and long-term investments of $237.0 million. 
Seekingalpha · 05/12 12:33
Thomas Steyer’s Farallon Capital is Buying These 10 Stocks
In this article, we discuss 10 stocks that Thomas Steyer’s Farallon Capital is buying. If you want to see some more of his latest stock picks, check out Thomas Steyer’s Farallon Capital is Buying These 5 Stocks. Thomas Steyer is an American investor, entre...
Insider Monkey · 04/20 14:16
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapie...
PR Newswire · 04/08 17:00
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today anno...
PR Newswire · 04/05 12:30
58 Biggest Movers From Friday
Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: DIDI) shares jumped 59.8% to settle at $4.09 on Friday.
Benzinga · 03/21 08:54
More
Webull provides a variety of real-time THRX stock news. You can receive the latest news about Theseus Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About THRX
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The Company's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.